Dr_Grip
Made from concentrate
- Joined
- Jul 8, 2008
- Messages
- 15,215
- Location
- HEL
- Car(s)
- 79 Opel Kadett|72 Ford Country Sedan|03 Volvo XC70
Some more good news among variant scares:
At the same time, Nature reports that:
Remark: "B.1351" and "501Y.V2" both refer to the same partial immune escape variant carrying the E484K mutation.
Business Insider said:Updated results from Pfizer's late-stage study of the coronavirus vaccine it developed with BioNTech indicate that the two-dose shot's overwhelming protection is holding up six months after the second dose.
The study has tallied 927 symptomatic cases of COVID-19 among the more than 46,000 trial volunteers. People who got placebo shots accounted for 850 of those cases, compared with 77 illnesses among those who received the vaccine. That translates to 91.3% efficacy, Pfizer and BioNTech said in a statement Thursday.
[...]
The trial also provides the first clinical data suggesting the Pfizer-BioNTech vaccine works against B.1.351, a variant first identified in South Africa that has caused some concern among virologists. [...] Pfizer's study enrolled 800 participants in South Africa, and nine of them came down with COVID-19. All nine of the cases happened in the placebo group. Researchers sequenced those strains and found six of the nine were the B.1.351 strain.
The Pfizer-BioNTech COVID-19 shot remains highly protective against the coronavirus, longer-term data shows
Six months after early trial participants got their second doses of the jab, Pfizer says the protection from its vaccine is strong and is holding up.
www.businessinsider.com
At the same time, Nature reports that:
Nature said:Antibodies from people infected with the 501Y.V2 coronavirus variant first identified in South Africa are also effective against previously circulating variants, suggesting that vaccines against 501Y.V2 might work against a range of coronavirus variants. [...]
The scientists also found that second-wave plasma could neutralize first-wave variants with an effectiveness similar to that of the Pfizer–BioNTech vaccine. This implies that updated vaccines against 501Y.V2 could also protect against earlier coronavirus variants.
Remark: "B.1351" and "501Y.V2" both refer to the same partial immune escape variant carrying the E484K mutation.
Last edited: